openPR Logo
Press release

Polymyositis Market Anticipated to Expand Rapidly During 2023-2032, Says DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer

06-19-2024 07:33 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Polymyositis Market Anticipated to Expand Rapidly During

DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan..

To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Polymyositis Market Report:
• The Polymyositis market size was valued approximately USD 88 million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As of 2022, there were around 184,204 reported cases of diagnosed prevalent Inflammatory Myositis in the 7MM (Seven Major Markets). Projections indicate an anticipated upward trend in these cases, with a notable compound annual growth rate (CAGR) expected during the forecast period from 2023 to 2032.
• Out of a total of 90,064 diagnosed prevalent cases of Inflammatory Myositis, Polymyositis constituted approximately 27,565 cases in the United States in 2022. It is anticipated that these cases will continue to rise at a significant compound annual growth rate (CAGR) over the entire forecast period from 2023 to 2032.
• Polymyositis MarketPolymyositis MarketDuring 2022, the European Union 4 (EU4) and the UnitedKingdom collectively represented 34,459 diagnosed prevalent cases of Polymyositis. Among the EU4 and the UK, Germany reported the highest total with 11,185 diagnosed prevalent cases of Polymyositis, while Spain had the lowest number, recording a total of 3,504 diagnosed prevalent cases.
• Arjenx is currently advancing Efgartigimod through Phase II/III clinical development, with an anticipated launch in the forecast period. This is expected to notably expand the evolving market for Polymyositis.
• Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer, Bristol-Myers Squibb, and others
• Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others
• The Polymyositis epidemiology based on gender analyzed that Polymyositis affects females more as compared to males
• The Polymyositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyositis pipeline products will significantly revolutionize the Polymyositis market dynamics.

Polymyositis Overview
Polymyositis is a rare inflammatory muscle disease characterized by muscle weakness and inflammation. It is classified as an idiopathic inflammatory myopathy, meaning its exact cause is unknown.

Get a Free sample for the Polymyositis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Polymyositis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polymyositis Epidemiology Segmentation:
The Polymyositis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Polymyositis
• Prevalent Cases of Polymyositis by severity
• Gender-specific Prevalence of Polymyositis
• Diagnosed Cases of Episodic and Chronic Polymyositis

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Epidemiology Forecast
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Polymyositis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyositis market or expected to get launched during the study period. The analysis covers Polymyositis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Polymyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polymyositis Therapies and Key Companies
• Efgartigimod: Argenx
• PF1801: Immunoforge Co. Ltd.
• tocilizumab: Chester Oddis
• KZR-616: Kezar Life Sciences, Inc.
• Adrenocorticotropic Hormone Gel: Mallinckrodt
• M5049 high dose: Merck KGaA
• Tacrolimus: Astellas Pharma Inc
• Rituximab: Genentech
• Froniglutide: Immunoforge Co. Ltd.
• PF-06823859: Pfizer
• Abatacept subcutaneous: Bristol-Myers Squibb

Discover more about therapies set to grab major Polymyositis market share @ Polymyositis Treatment Landscape
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Polymyositis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer, Bristol-Myers Squibb, and others
• Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others
• Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies
• Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Polymyositis Unmet Needs, KOL's views, Analyst's views, Polymyositis Market Access and Reimbursement

To know more about Polymyositis companies working in the treatment market, visit @ Polymyositis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Polymyositis Market Report Introduction
2. Executive Summary for Polymyositis
3. SWOT analysis of Polymyositis
4. Polymyositis Patient Share (%) Overview at a Glance
5. Polymyositis Market Overview at a Glance
6. Polymyositis Disease Background and Overview
7. Polymyositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Polymyositis
9. Polymyositis Current Treatment and Medical Practices
10. Polymyositis Unmet Needs
11. Polymyositis Emerging Therapies
12. Polymyositis Market Outlook
13. Country-Wise Polymyositis Market Analysis (2019-2032)
14. Polymyositis Market Access and Reimbursement of Therapies
15. Polymyositis Market Drivers
16. Polymyositis Market Barriers
17. Polymyositis Appendix
18. Polymyositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Polymyositis Pipeline https://www.delveinsight.com/report-store/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Polymyositis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Polymyositis market. A detailed picture of the Polymyositis pipeline landscape is provided, which includes the disease overview and Polymyositis treatment guidelines.

Latest Reports by DelveInsight

Cart-related Neurotoxicity Market https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
DelveInsight's "CART-related Neurotoxicity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CART-related Neurotoxicity, historical and forecasted epidemiology as well as the CART-related Neurotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

H3n2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
DelveInsight's "H3N2 Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the H3N2 Infection, historical and forecasted epidemiology as well as the H3N2 Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
DelveInsight's "Liver Angiosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Liver Angiosarcoma, historical and forecasted epidemiology as well as the Liver Angiosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Undifferentiated Pleomorphic Sarcoma, historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Polymyositis Market Anticipated to Expand Rapidly During 2023-2032, Says DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer here

News-ID: 3545378 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Polymyositis

Polymyositis Market Outlook 2025-2034: Trends, Growth, and Forecast Analysis
Polymyositis (PM) is a rare, chronic autoimmune disease that causes muscle weakness and inflammation. It affects the muscles responsible for movement, leading to significant disability and a reduction in quality of life. As the understanding of autoimmune diseases expands and new therapeutic options emerge, the polymyositis market is experiencing significant growth. This article explores the key drivers, market trends, challenges, and growth opportunities in the polymyositis market, projected to expand
Polymyositis Market Size Forecasted To Achieve $2.23 Billion By 2029 With Steady …
The Polymyositis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Polymyositis Market Size and Projected Growth Rate? The market size for polymyositis has experienced solid growth in previous years. The market is projected to rise from $1.65 billion in 2024 to $1.75 billion
Polymyositis Clinical Pipeline | 7+ Innovators Pushing the Boundaries of Treatme …
The Polymyositis market is advancing with groundbreaking research and innovative therapeutic developments. DelveInsight's 'Polymyositis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Polymyositis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Polymyositis pipeline domain. For Polymyositis emerging drugs, the Polymyositis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product
Polymyositis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Polymyositis Pipeline Insight 2024" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Polymyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Polymyositis Research. Learn more about our innovative pipeline
Polymyositis Treatment Market Size Research Report 2024
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Polymyositis Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Polymyositis Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Polymyositis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Polymyositis market size from 2019 to 2032, segmented